M. Dion

Adverse Events with 4 Months of Rifampin Therapy or 9 Months of Isoniazid Therapy for Latent Tuberculosis Infection

K. Khan, R. Long, Z. Memish, 2008, Annals of Internal Medicine.

months isoniazid for latent TB randomised trial of 4 ? months rifampin or adverse events on health system costs in a Impact of treatment completion , intolerance and

K. Khan, R. Long, K. Schwartzman, 2022 .

Profiles of Neurological Outcome Prediction Among Intensivists

J. Illes, E. Racine, M. Lansberg, 2009, Neurocritical care.

Randomized trial of a lifestyle intervention for women with early-stage breast cancer (BC) receiving adjuvant hormone therapy: Initial results.

G. Pond, P. Goodwin, K. Pritchard, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

P4-12-05: Impact of the Lifestyle Intervention Study in Adjuvant Treatment of Early Breast Cancer (LISA) Weight Loss Intervention upon Physical Activity.

G. Pond, P. Goodwin, K. Pritchard, 2011 .

Epidemic History and Iatrogenic Transmission of Blood-borne Viruses in Mid-20th Century Kinshasa.

O. Pybus, A. Rambaut, F. Behets, 2016, The Journal of infectious diseases.

Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults

R. Long, A. Benedetti, H. Kim, 2018, The New England journal of medicine.

Feasibility and reliability of health-related quality of life measurements among tuberculosis patients

J. Bourbeau, K. Schwartzman, D. Menzies, 2004, Quality of Life Research.

Measurement of Health Preferences among Patients with Tuberculous Infection and Disease

Kevin Schwartzman, Dick Menzies, J. Bourbeau, 2002, Medical decision making : an international journal of the Society for Medical Decision Making.

Impact of treatment completion, intolerance and adverse events on health system costs in a randomised trial of 4 months rifampin or 9 months isoniazid for latent TB

K. Khan, R. Long, K. Schwartzman, 2010, Thorax.

Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months.

K. Schwartzman, D. Menzies, B. Rabinovitch, 2004, American journal of respiratory and critical care medicine.

Factors associated with treatment adherence in a randomised trial of latent tuberculosis infection treatment.

R. Long, A. Trajman, D. Menzies, 2010, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

In closely monitored patients, adherence in the first month predicts completion of therapy for latent tuberculosis infection.

K. Schwartzman, D. Menzies, I. Rocher, 2005, The International Journal of Tuberculosis and Lung Disease.

Profiles of Neurological Outcome Prediction Among Intensivists

J. Illes, E. Racine, M. Lansberg, 2009, Neurocritical care.